Patents by Inventor PROCOM ONE, INC.

PROCOM ONE, INC. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DOXEPIN ISOMERS AND ISOMERIC MIXTURES AND METHODS OF USING THE SAME TO TREAT SLEEP DISORDERS
    Publication number: 20130102658
    Abstract: The invention relates to use of the cis-(Z) isomer or isomeric mixtures containing specified ratios of the cis-(Z) and trans-(E) isomers of doxepin, metabolites of doxepin, pharmaceutically-acceptable salts of doxepin and prodrugs of the same; compositions containing the same, for the treatment of sleep disorders
    Type: Application
    Filed: December 3, 2012
    Publication date: April 25, 2013
    Applicants: PROCOM ONE, INC., SOMAXON PHARMACEUTICALS, INC.
    Inventors: Somaxon Pharmaceuticals, Inc., ProCom One, Inc.
  • DOXEPIN TRANS ISOMERS AND ISOMERIC MIXTURES AND METHODS OF USING THE SAME TO TREAT SLEEP DISORDERS
    Publication number: 20130096188
    Abstract: The invention relates to use of the trans-(E) isomer or isomeric mixtures containing specified ratios of the trans-(E) and cis-(Z) isomers of doxepin, metabolites of doxepin, pharmaceutically-acceptable salts of doxepin and prodrugs of the same; compositions containing the same, for the treatment of sleep disorders
    Type: Application
    Filed: December 3, 2012
    Publication date: April 18, 2013
    Applicants: ProCom One, Inc., Somaxon Pharmaceuticals, Inc.
    Inventors: Somaxon Pharmaceuticals, Inc., ProCom One, Inc.
  • LOW-DOSE DOXEPIN FOR TREATMENT OF SLEEP DISORDERS IN ELDERLY PATIENTS
    Publication number: 20130018090
    Abstract: Methods of treating sleep disorders, particularly certain aspects of insomnia, in elderly patients (65 years and older) by administering initial daily dosages of doxepin of 1-3 mg. These ultra-low initial dosages are more effective in elderly versus non-elderly patients in decreasing wake time during sleep, latency to persistent sleep and wake time after sleep, and are particularly efficacious in treating those conditions in the last hour of an 8-hour sleep cycle. Also, the dosages described herein are safe for elderly individuals.
    Type: Application
    Filed: September 17, 2012
    Publication date: January 17, 2013
    Applicants: PROCOM ONE, INC., SOMAXON PHARMACEUTICALS, INC.
    Inventors: SOMAXON PHARMACEUTICALS, INC., PROCOM ONE, INC.